Table 1. Base Case Results of Cost-effectiveness Analysis.
| Procedure | BCR rate, % | Recurrence-free duration, y | Life-years | QALY | Direct costs, £ (US $) | ICER, £ (US $) | INMB, £/US $a | ||
|---|---|---|---|---|---|---|---|---|---|
| Total | Incremental | Total | Incremental | ||||||
| RARP | 28 | 8.02 | 9.22 | 7.93 | NA | 13 247 (17 443) | NA | RARP dominant | 8993/ (11 842) |
| LRP | 37 | 7.33 | 9.09 | 7.69 | 0.24 | 15 032 (19 794) | −1785 (−2350) | ||
| RARP | 28 | 8.02 | 9.22 | 7.93 | NA | 13 247 (17 443) | NA | 4293 (5653) | 3149 (4146) |
| ORP | 32 | 7.75 | 9.17 | 7.81 | 0.12 | 12 721 (16 751) | 526 (693) | ||
Abbreviations: BCR, biochemical recurrence; ICER, incremental cost-effectiveness ratio; INMB, incremental net monetary benefit; LRP, laparoscopic radical prostatectomy; NA, not applicable; ORP, open radical prostatectomy; QALY, quality-adjusted life-year; RARP, robotic-assisted radical prostatectomy.
a
Calculated at the willingness-to-pay threshold of less than £30 000 (US $39 503)/QALY gained.